The University of Texas System

Millennium Pharmaceuticals Limited

Cytovia, Inc.

Nanostring Technologies, Inc.

University of California

University of South Florida

Mayo Foundation for Medical Education and Research

The Cleveland Clinic Foundation

Lpath, Inc.

Bruker Spatial Biology, Inc.

Ut Board of Regents

Gordon B Mills

Robert C Bast

Eckard Weber

Joseph M Beechem

Dwayne L Dunaway

Douglas R Green

Jaemyeong Jung

Charles Warren

Chris Merritt

Scott Crowder

Sui Xiong Cai

Yan Wang

Lynn C Hartmann

Ole Petter Veiby

Edwin A Clark

Gabriel N Hortobagyi

Karen Lu

Joe W Gray

Jeffrey L Brown

Shiaw-Yih Lin

Tallessyn Grenfell-Lee

Kristina Sorg

William A Garland

Roger A Sabbadini

Genevieve Hansen

Andrew I Damokosh

Laleh Shayesteh

Bruce J Holub

Yan Xu

Graham Casey

Meera Nanjundan

Rosalia Matteo

James Stephen Swaney

Jonathan Michael Wojciak

Yinghui Guan

Wen-Lin Kuo

Natalia Iartchouk

Daniel McGrail

Chun-Jen Lin

Guang Peng

Jane Fridlyand

Dawn Smith

Yiling Lu

James J Stec, Ii

Hong-Ji Xu

Shi-Xue Hu

Lufeng Guan

Douglas C Gaudette

The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue

The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein and/or nucleic acid expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue

Methods for identifying and treating cancers that are DNA repair, such as homologous recombination (HR) repair, defective or sensitive to PARP inhibitors or platinum-based therapy. In some aspects, DNA repair, such as HR repair, defective cancers are treated with a PARP inhibitor therapy or cisplatin. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

Gene signatures to predict drug response in cancer

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.

Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

Gene signature to predict homologous recombination (HR) deficient cancer

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Compositions and methods for binding lysophosphatidic acid

Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.

Predictive and therapeutic markers in ovarian cancer

Genomic analysis of ovarian cancers demonstrated a regional chromosomal increase in expression and gene duplication. TGF-&#x3b2; stimulation indicated a link between SnoN RNA and TGF-&#x3b2;. In TIOSE, SnoN protein levels were reduced 15 min post TGF-&#x3b2;-stimulation, likely by proteosome-mediated degradation. SnoN inhibition decreased cell growth between 20 and 50% concurrent with increased p21 levels. Stable expression of SnoN led to growth arrest through induction of senescence. Collectively, these results implicate SnoN levels in multiple roles during ovarian carcinogenesis: promoting cellular proliferation in ovarian cancer cells and as a positive mediator of cell cycle arrest and senescence in non-transformed ovarian epithelial cells.

Methods of treating ovarian cancer by modulating SnoN

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

Compositions and methods for the identification, assessment, prevention and therapy of human cancers

The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.

Genetic alterations associated with cancer

Growing community of inventors

Houston, TX, United States of America

Gordon B Mills